OPPM
NBIX icon

Opus Point Partners Management’s Neurocrine Biosciences NBIX Stock Holding History

Opus Point Partners Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$282K Buy
3,127
+115
+4% +$10.7K 0.51% 41
2019
Q2 		$254K Buy
3,012
+205
+7% +$16.8K 0.38% 58
2019
Q1 		$247K Sell
2,807
-179
-6% -$15K 0.33% 69
2018
Q4 		$213K Sell
2,986
-405
-12% -$38.8K 0.47% 36
2018
Q3 		$417K Buy
3,391
+326
+11% +$37K 1% 29
2018
Q2 		$301K Sell
3,065
-167
-5% -$14.9K 0.65% 36
2018
Q1 		$268K Sell
3,232
-972
-23% -$82.1K 0.53% 44
2017
Q4 		$326K Sell
4,204
-5,440
-56% -$371K 0.28% 45
2017
Q3 		$591K Buy
9,644
+4,469
+86% +$236K 0.53% 43
2017
Q2 		$238K Sell
5,175
-4,009
-44% -$194K 0.22% 58
2017
Q1 		$398K Buy
9,184
+3,047
+50% +$131K 0.3% 50
2016
Q4 		$238K Buy
6,137
+2,069
+51% +$93.7K 0.19% 53
2016
Q3 		$206K Buy
+4,068
New +$203K 0.12% 46

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opus Point Partners Management's NBIX Position: Q3 2019 in Review

Opus Point Partners Management increased its Neurocrine Biosciences (NBIX) stake by 3.8% in Q3 2019, buying an estimated $10.7K and bringing the position to 3,127 shares worth $282K. The position accounts for 0.51% of the portfolio, ranked #41.

Opus Point Partners Management first reported a position in NBIX in Q3 2016 and has held it in 13 quarters since. The position peaked at $591K in Q3 2017. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Opus Point Partners Management held 3,127 shares of Neurocrine Biosciences worth $282K as of Q3 2019.
  • Opus Point Partners Management bought 115 Neurocrine Biosciences shares in Q3 2019, an estimated $10.7K.
  • Neurocrine Biosciences made up 0.51% of Opus Point Partners Management's portfolio in Q3 2019, its #41 holding.
  • Opus Point Partners Management first reported a position in Neurocrine Biosciences in Q3 2016 and has held it in 13 quarters since.
  • Opus Point Partners Management's Neurocrine Biosciences position peaked at $591K in Q3 2017.
  • 333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.